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Abstract
Increasing evidence has pointed to activated type I interferon signaling in tumors. However, the molecular basis for such
activation and its role in tumorigenesis remain unclear. In the current studies, we report that activation of type I interferon
(IFN) signaling in tumor cells is primarily due to elevated secretion of the type I interferon, IFN-b. Studies in oncogene-
transformed cells suggest that oncogenes such as Ras and Src can activate IFN-b signaling. Significantly, elevated IFN-b
signaling in Ras-transformed mammary epithelial MCF-10A cells was shown to contribute to Ras transformation as
evidenced by morphological changes, anchorage-independent growth, and migratory properties. Our results demonstrate
for the first time that the type I IFN, IFN-b, contributes to Ras transformation and support the notion that oncogene-induced
cytokines play important roles in oncogene transformation.
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Introduction
Increasing evidence has indicated up-regulated type I interferon
(IFN) signaling in many tumors. For example, transcriptional
profiling studies of invasive squamous cell carcinoma of the skin
have demonstrated elevated expression of IFN-regulated genes [1].
Enhanced IFN signaling has also been suggested in a proteomic
study of oral squamous cell carcinoma [2]. Most notably, ISG15
(interferon-stimulated gene 15), has been shown to be a new tumor
marker for many cancers [3]. ISG15, whose expression is
controlled by type I interferons, is an ubiquitin-like protein
(UBL). Unlike ubiquitin whose expression is more or less constant
in all cells, ISG15, which is undetectable in most normal tissues
[4], is highly expressed, albeit with a high degree of heterogeneity,
in both tumor cell lines and tumor biopsies. For example, among a
panel of breast cancer cell lines, ISG15 is highly expressed in ZR-
75-1 and MDA-MB-231, but not in BT-474 cells [4]. In addition,
studies of biopsy samples have demonstrated that ISG15 is highly
elevated and variably expressed in endometrium tumors, but non-
detectable in their normal counterpart tissues [4]. Similar analysis
has also revealed highly elevated expression of ISG15 in bladder,
prostate and oral cancers [2,5,6]. Transcriptomic dissection of the
head and neck/oral squamous cell carcinoma (HNOSCC) has also
identified the ISG15 gene as an up-regulated gene [7].
Furthermore, elevated ISG15 expression in bladder cancers shows
a positive correlation with the stages of the disease [5].
Significantly, ISG15 has been shown to be a prognostic marker
for breast cancer [8].
Elevated ISG15 expression in various tumors suggests up-
regulation of type I IFN signaling in these tumors. However, the
molecular basis for ISG15 overexpression and activated IFN
signaling in tumors remains unclear. One possibility is that
elevated expression of ISG15 and hence increased IFN signaling in
tumors is linked to oncogene activation. Oncogenes, such as Ras,
are known to cause cellular transformation (e.g. morphological
changes and anchorage-independent growth) and play a key role
in tumorigenesis [9]. More recently, the involvement of Ras in
cancer invasion and metastasis has also been suggested through
studies of oncogene-induced epithelial-mesenchymal transition
(oncogenic EMT) in several model systems [10,11]. Tumor cells
also appear to acquire EMT characteristics during tumor invasion
and metastasis, and many EMT markers such as Snail (a
transcription factor) and E-cadherin are known to be dysregulated
in metastatic tumors [12,13,14,15].
In the current studies, we show that oncogenic Ras induces
elevated ISG15 expression in human mammary epithelial MCF-
10A cells due to IFN-b signaling. Furthermore, we show that IFN-
b signaling through ISG15 contributes positively to Ras transfor-
mation and oncogenic EMT in MCF-10A cells, supporting the
notion that oncogene-induced cytokines play important roles in
oncogene transformation.
Results
ISG15 overexpression in breast cancer ZR-75-1 cells is
due to elevated IFN-b signaling
Previous studies have demonstrated that ISG15 is highly, but
variably, overexpressed in tumor tissues and tumor cell lines [3,4].
As shown in Fig. 1A, ISG15 is variably expressed in three breast
cancer cell lines, with ISG15 expression being the highest in
ZR-75-1 as compared to BT474 and T47D. The following
observations suggest that ISG15 overexpression in ZR-75-1 cells is
due to elevated interferon-b signaling: (1) We found that the
ISG15 level (normalized to a-tubulin) in breast cancer ZR-75-1
cells increased with increasing culturing time (Fig. 1B). The
possibility that a cytokine is involved is further suggested from the
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ZR-75-1 cells, but not BT474 or T47D cells, were able to elevate
ISG15 expression in freshly seeded ZR-75-1 cells (Fig. 1C). (2)
Culturing of ZR-75-1 cells in the presence of IFN-b-, but not IFN-
a-, neutralizing antibodies strongly reduced ISG15 expression
(Fig. 1D), suggesting that IFN-b is secreted by ZR-75-1 cells and is
responsible for elevated ISG15 expression. This notion was further
supported by an interferon antiviral assay which showed the
presence of IFN-b, but not IFN-a, in the ZR-75-1 cell-conditioned
medium (Fig. 1E). (3) siRNA-mediated knockdown of IFNAR1
[interferon (alpha, beta and omega) receptor 1], one of the two
chains of the type I IFN receptor, in ZR-75-1 cells resulted in a
significant reduction of ISG15 expression (Fig. 1F), suggesting that
interferon signaling through the receptor is involved in ISG15
overexpression in ZR-75-1 cells. In the aggregate, these results
suggest that ISG15 overexpression in ZR-75-1 breast cancer cells
is due to elevated IFN-b signaling.
Src and Ras oncogenes stimulate ISG15 expression in
cultured mammalian cells
In order to determine the molecular basis for ISG15 up-
regulation in tumor cells, we have evaluated the effect of
oncogenes on ISG15 expression in cultured mammalian cells.
Temperature-sensitive viral Src (ts-v-Src)-transformed rat intesti-
nal epithelial (RIE) cells were used to determine the effect of the
Src oncogene on ISG15 expression. At the permissive temperature
(35uC), ts-v-Src cells, which are known to maintain its Src kinase
activity and transformation phenotype [16], expressed a high level
of ISG15 as compared to untransformed RIE cells (Fig. 2A). In
addition, at the non-permissive temperature (41uC), ts-v-Src cells
expressed a lower level of ISG15, similar to that of the
untransformed RIE cells (Fig. 2A). These results suggest that
ISG15 overexpression could be linked to oncogene activation.
To further test whether Ras may up-regulate ISG15, NIH 3T3
cells were transiently transfected with either the control vector
(pMV-7) or the v-Ha-Ras expression vector (pv-Ha-Ras). As
shown in Fig. 2B, ISG15 is greatly elevated in v-Ha-Ras-
transfected NIH 3T3 cells as compared to vector-transfected
control cells. In support of the transient transfection results, NIH
3T3 cells stably transfected with v-Ha-Ras (v-Ras) expressed a
much higher level of ISG15 as compared to NIH 3T3 control cells
(Fig. 2C). Furthermore, a similar study was performed using
human mammary epithelial MCF-10A cells. As shown in Fig. 2E,
MCF-10A cells transiently transfected with either H-RasR12
(expressing activated H-Ras) or K-RasV12 (expressing activated
K-Ras) expressed higher ISG15 levels as compared to MCF-10A
cells transfected with the control vector (pCEV29). Consistent with
the transient transfection results, MCF-10A cells stably transfected
with either H-RasR12 (designated 10A/H-Ras cells) or K-RasV12
(designated 10A/K-Ras cells) expressed much higher levels of
ISG15 as compared to MCF-10A cells stably transfected with the
control vector pCEV29 (designated 10A/Ct) (Fig. 2F). In addition,
Figure 1. Elevated ISG15 expression in breast cancer cells is due to interferon-b (IFN-b) secretion. Breast cancer ZR-75-1, BT474, and
T47D cells were used in the current studies. A. ISG15 is overexpressed in ZR-75-1 cells as compared to BT474 and T47 D cells. Steady-state levels of
ISG15 were measured by immunoblotting using anti-ISG15 antibodies. B. Time-dependent increase in ISG15 expression in cultured ZR-75-1 cells.
Breast cancer ZR-75-1 cells were harvested at different time intervals after seeding, and cell lysates were analyzed by immunoblotting with anti-ISG15
antibodies. C. Conditioned media from cultured ZR-75-1 cells stimulate ISG15 expression. Breast cancer ZR-75-1, BT474, and T47D cells were seeded at
equal density and cultured for 3 days. Conditioned media were collected individually and filtered through 0.2 mm Corning syringe filters. The newly
(16 hrs) seeded ZR-75-1 cells were then replenished with the conditioned media. Lysates were collected 3 days later and analyzed by immunoblotting
with anti-ISG15 antibodies. D. Antibody neutralization of IFN-b inhibits ISG15 expression in tumor cells. ZR-75-1 cells were cultured for 3 days in the
presence of neutralizing antibodies against human IFN-a or human IFN-b (100 NU/ml). Cell lysates were immunoblotted with anti-ISG15 antibodies. E.
Elevated IFN-b is present in the conditioned medium from ZR-75-1 cells. Conditioned media from different breast cancer cells, ZR-75-1, BT474, and
T47D were individually collected after 3 days of culturing. The media were assayed for IFN-a and IFN-b using the interferon antiviral assay as
described in Materials and Methods. F. The interferon receptor is required for elevated ISG15 expression in ZR-75-1 cells. Breast cancer ZR-75-1 cells
were transiently transfected with control or IFNAR1 siRNA. Cell lysates were collected 72 hrs post-transfection and immunoblotted with anti-ISG15
antibodies.
doi:10.1371/journal.pone.0024291.g001
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characterized H-Ras-transformed MCF-10A (MCF-10AT) cell
line [17] as compared to its untransformed control line (MCF-
10A) (Fig. 2D). Taken together, these results strongly suggest that
oncogenic Ras stimulates ISG15 expression.
Oncogenic Ras-induced ISG15 overexpression requires
IFN-b signaling
As demonstrated in Fig. 1, overexpression of ISG15 in ZR-75-1
cells is due to elevated IFN-b secretion and activation of the type I
IFN signaling. To determine whether Ras-induced ISG15
overexpression is also due to elevated IFN-b signaling, IFN-b
and IFNAR1 were silenced by their specific siRNAs in Ras-
transformed MCF-10A cells (10A/H-Ras and 10A/K-Ras). As
shown in Fig. 3, knocking down either IFN-b (Fig. 3A) or IFNAR1
(Fig. 3B) in oncogenic Ras-(H-Ras- or K-Ras-) transformed cells
resulted in decreased expression of ISG15. These results suggest
that elevated IFN-b signaling is responsible for ISG15 overex-
pression in oncogenic Ras-transformed MCF-10A cells.
In addition to the involvement of IFN-b and IFNAR1, the Ras
downstream signals necessary for ISG15 overexpression was also
investigated using specific inhibitors. Oncogenic Ras-transformed
MCF-10A cells were treated with LY294002, a PI3K inhibitor.
Interestingly, the ISG15 level was reduced by the PI3K inhibitor
(labeled L) in both Ras-transformed lines (Fig. 3C), suggesting
that the PI3K signaling pathway is involved in ISG15 induction in
Ras-transformed MCF-10A cells. Since NF-kB is known to
regulate IFN-b expression through its binding to the IFN-b
promoter, we also investigated the possible involvement of NF-kB
in Ras-induced ISG15 overexpression [18]. As shown in Fig. 3D,
treatment of both H- and K-Ras-transformed MCF-10A cells with
the NF-kB inhibitor, Bay 11-7085, resulted in significant reduction
of the ISG15 level, suggesting a possible involvement of NF-kBi n
Ras-induced ISG15 overexpression in MCF-10A cells. Together,
these results suggest that PI3K and NF-kB are potential Ras
downstream signals necessary for ISG15 overexpression in Ras-
transformed MCF-10A cells.
IFN-b signaling modulates Ras transformation in MCF-
10A cells
Ras transformation is known to result in major cell morphology
changes and anchorage-independent growth [9]. To investigate a
possible role of IFN-b signaling in Ras transformation, we
transiently knocked down IFN-b, IFNAR1 or ISG15, and
monitored cellular morphology and colony formation (in both
attached and suspended conditions) in K-Ras-transformed MCF-
10A cells (10A/K-Ras). As shown in Fig. 4A, the percentage of
spindle-shaped cells in 10A/K-Ras population was around 45% as
compared to 5% in 10A/Ct population. The percentage of
spindle-shaped cells was reduced to 13, 15, and 22% when IFN-b,
IFNAR1 and ISG15 were knocked down by their respective
siRNAs in 10A/K-Ras cells. By contrast, the percentage of
Figure 2. Oncogenic Ras elevates ISG15 expression. A. v-Src induces ISG15 expression in rat intestinal epithelial (RIE) cells. The RIE cell line and
its ts-v-Src-transformed variant were cultured at different temperatures (35uC and 41uC) for 3 days. Lysates were analyzed by immunoblotting using
anti-ISG15 antibodies. B. Oncogenic Ras induces ISG15 expression in transiently transfected NIH 3T3 cells. Murine fibroblast NIH 3T3 cells were
transiently transfected with the vector or v-Ha-Ras plasmid using Polyfect (Qiagen) following the manufacturer’s instructions. Cell lysates were
collected 2 days post-transfection and immunoblotted with anti-ISG15 antibodies. C. Elevated ISG15 expression in oncogenic Ras-transformed NIH
3T3 cells. Oncogenic v-Ha-Ras-transformed and control NIH 3T3 cells were cultured for 2 days. Cell lysates were immunoblotted with anti-ISG15
antibodies. D. Elevated ISG15 expression in the H-Ras transformed MCF-10AT cell line. Cells were seeded equally and harvested 2 days later. Lysates
were immunoblotted with anti-ISG15 antibodies. E. Transient transfection with Ras oncogenes (H-RasR12 and K-RasV12) induces ISG15 in mammary
epithelial cells. Human mammary epithelial MCF-10A cells were transiently transfected with oncogenic Ras-expressing plasmids using FuGene (Roche)
as described in Materials and Methods. Two days post-transfection, cell lysates were immunoblotted with anti-ISG15 antibodies. F. Oncogenic Ras-
transformed mammary epithelial MCF10A cells overexpress ISG15. The oncogenic Ras-transformed MCF-10A (10A/H-Ras and 10A/K-Ras) were
established as described in Materials and Methods. Culturing conditions and Western blotting were performed as described in D.
doi:10.1371/journal.pone.0024291.g002
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was nearly unchanged (43%), suggesting that the cell morphology
change upon Ras transformation is dependent on IFN-b, IFNAR1
and ISG15. To determine if IFN-b signaling may contribute to
anchorage-independent growth in Ras-transformed MCF-10A
cells, soft agar colony formation assay was performed. As shown in
Fig. 4B, 10A/K-Ras cells formed about 11 times more colonies in
soft agar than 10A/Ct cells. However, siRNA-mediated knock-
down of IFN-b, IFNAR1 or ISG15 reduced the colony formation
efficiency of 10A/K-Ras cells to 50-70% (Fig. 4B). We also
performed the colony formation assay on plastic surfaces. As
shown in Fig. 4C, sparsely seeded 10A/K-Ras cells clearly formed
more colonies than 10A/Ct cells (about 4-fold difference). The
colony formation efficiency was reduced to about 70% when IFN-
b, IFNAR1 or ISG15 was knocked down in 10A/K-Ras cells. All
results are statistically significant (p-value ,0.05, marked by *)
with the possible exception of the IFNAR1 knockdown result (p-
value=0.07) in soft agar assay (Fig. 4B). These results suggest that
IFN-b signaling contributes significantly to Ras-transformation in
MCF-10A cells.
IFN-b signaling contributes to migratory properties of
Ras-transformed MCF-10A cells
Ras is known to confer increased cell migration and oncogenic
epithelial-mesenchymal transition (EMT), which have been linked
to tumor invasion and metastasis [10]. In order to determine a
possible role of IFN-b signaling in oncogenic EMT, we have
monitored the effect of IFN-b signaling on increased cell migration
and appearance of the EMT marker E-cadherin in 10A/K-Ras
cells. Cell migration was assessed by a wound healing assay (see
Materials and Methods). As shown in Fig. 5A, the wound area of
10A/Ct cells was reduced to about 40% 12 hrs post-wounding. By
contrast, the wound area of 10A/K-Ras was nearly completely
closed (reduced to about 6%), suggesting that 10A/K-Ras cells
migrate faster than 10A/Ct cells. When IFN-b, IFNAR1 or ISG15
was knocked down by their respective siRNA in 10A/K-Ras cells,
the wound area was reduced to the level of the control 10A/Ct
cells (about 50%), suggesting that IFN-b signaling contributes
positively to increased cell migration in Ras-transformed cells.
We have also assessed the effect of IFN-b signaling on the
appearance of the key EMT marker E-cadherin in Ras-
transformed MCF-10A cells [12,19]. As shown in Fig. 5C, E-
cadherin was shown to be down-regulated in 10A/K-Ras cells and
silencing of IFN-b, IFNAR1 or ISG15 resulted in significant
restoration of the E-cadherin protein level as evidenced by both
immunoblotting (Fig. 5C) and immunofluorescence (Fig. 5B, note
the red E-cadherin staining on cellular surfaces) using anti-E-
cadherin antibodies. In the aggregate, these results suggest that
IFN-b signaling through ISG15 contributes to the migratory
properties of Ras-transformed MCF-10A cells.
Discussion
The demonstration of ISG15 as a tumor marker immediately
suggests that the type I IFN signaling pathway may be up-
regulated in tumors. Indeed, transcription profiling studies have
demonstrated up-regulation of type I IFN-regulated genes in some
tumors [1]. Our current studies have suggested that the increased
secretion of IFN-b with subsequent activation of the type I IFN
signaling pathway is responsible for ISG15 overexpression in
breast cancer ZR-75-1 cells. We have also asked the question
whether the elevated ISG15 expression in tumor cells could be due
to oncogene activation. Indeed, we have shown that both Src and
Ras can stimulate ISG15 expression in tissue culture cells. Using
oncogenic Ras-transformed human mammary epithelial MCF-
10A cells, we have further demonstrated that oncogenic Ras up-
regulates ISG15 due to activation of IFN-b signaling through the
type I IFN receptor, IFNAR. In addition to Src and Ras as
demonstrated in the current studies, E1A has previously been
shown to cause elevated expression of IFN-b and ISG15 in the
adenovirus type 5 (Ad5)-transformed rodent cells [20]. Taken
together, these results suggest that oncogenes can up-regulate
ISG15 through elevated expression of IFN-b.
In our current studies, we have demonstrated for the first time
that IFN-b signaling through ISG15 contributes positively to
Figure 3. Identification of the effectors for ISG15 induction in the Ras-dependent signaling pathway. A, B. siRNA knock-down of
interferon-b and the type I IFN receptor reduces ISG15 induction in the Ras-dependent signaling pathway. The oncogenic Ras-transformed MCF-10A
cells (10A/H-Ras and 10A/K-Ras) were transiently transfected with control, IFN-b or IFNAR1 siRNA. Cell lysates were collected 72 hrs post-transfection
and immunoblotted with anti-ISG15 and anti-IFNAR1 antibodies. C. The PI3K inhibitor reduces ISG15 expression in oncogenic Ras-transformed cells.
10A/H-Ras and 10A/K-Ras cells were treated with 20 mM LY294002, a PI3K inhibitor, for 3 days. Lysates with equal protein amount were
immunoblotted with anti-ISG15 antibodies (L: LY294002). D. The NF-kB inhibitor reduces ISG15 expression in oncogenic Ras-transformed cells. 10A/H-
Ras and 10A/K-Ras cells were seeded and cultured overnight. Cells were then treated with or without 40 mM Bay 11-7085, an NF-kB inhibitor, for
24 hrs. Cell lysates were analyzed by immunoblotting using anti-ISG15, phospho-IkBa, and IkBa antibodies.
doi:10.1371/journal.pone.0024291.g003
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anchorage-independent growth) in Ras-transformed MCF-10A
cells. Our studies have also demonstrated that elevated IFN-b
signaling through ISG15 contributes significantly to cell morphol-
ogy changes, cell migration properties and reduced expression of
the EMT marker E-cadherin. Since oncogenic EMT has been
suggested to play an important role in tumor invasion and
metastasis [10], our results could implicate a role of IFN-b
signaling in tumor progression.
In our studies, oncogenic Ras appears to stimulate IFN-b
expression and secretion through activation of the PI3K/NF-kB
pathway. PI3K, which can be directly activated by Ras, is known
to control IRF-3, an important transcription factor regulating
IFN-b expression [21]. However, PI3K is also known to activate
NF-kB [22], a transcription factor which is found active in many
types of tumors and associated with tumor phenotypes [23].
Among different type I IFN genes, the NF-kB binding site is found
on the IFN-b, but not the IFN-a, promoter [24]. Our results thus
suggest that active NF-kB may be an important regulator in this
oncogene-induced IFN-b signaling. In this regard, it is interesting
to point out that oncogenic Ras has been shown to induce IL-6
and IL-8, both of which are NF-kB-regulated genes and shown to
promote Ras transformation and tumor growth [25,26,27].
Interestingly, the type I IFN, IFN-a, has been shown to induce
IL-6 in myeloma cells [28]. It seems likely that the complex
interplay among various oncogene-induced cytokines is critical for
oncogene transformation and tumorigenesis.
Our results, which demonstrate a positive role of type I IFN
signaling in oncogene transformation and oncogenic EMT, could
suggest therapeutic strategies for cancer treatment by antagonizing
the type I IFN signaling pathway in tumor cells. However, type I
IFNs are known to suppress tumor growth and IFN-a (i.e. IFN-a2)
has been used for the treatment of several cancers [29]. Several
possibilities could explain this apparent paradox: (1) The effect of
type I IFNs on tumor cell growth could be concentration-
dependent. At high concentrations such as those used in IFN
therapy, type I IFNs could suppress tumor growth through
stimulation of complex immune responses against the tumors (e.g.
up-regulation of tumor antigen presentation through MHC class I
molecules) and inhibition of tumor cell proliferation [29]. At lower
concentrations, IFNs may contrastingly stimulate tumor growth
[30]. Indeed, only low concentrations of type I IFNs have been
shown to stimulate the clonogenic tumor growth in vitro in a
fraction (6-28%) of human tumor samples tested [30]. Our current
results, which demonstrate a positive role of the IFN-b signaling in
oncogenic transformation and EMT, are consistent with the
growth stimulatory effect of IFNs at lower concentrations. (2) IFN-
a and IFN-b may exhibit different or opposite effects on tumor cell
growth, despite the fact that they share the same receptor for
signaling. Indeed, it has been reported that the gene expression
patterns induced by low concentrations of IFN-a and IFN-b
overlap but are not identical [31]. In addition, while IFN-a is used
for cancer therapy, IFN-b is used for treatment of multiple
sclerosis [32]. (3) The effect of type I IFNs on tumor cell growth
Figure 4. IFN-b autocrine signaling through ISG15 contributes to Ras transformation. A. Oncogenic Ras-induced morphological changes
are reversed by siRNA-mediated knockdown of IFN-b, IFNAR1 or ISG15. 10A/K-Ras cells were transiently transfected with control, IFN-b, IFNAR1 or
ISG15 siRNA. Images of cell morphology were taken three days later. Some of the cells with spindle-shaped morphology are indicated by arrows in
10A/K-ras cells treated with (third panel) and without (second panel) control siRNA (Ct. siRNA). Percentages of spindle-shaped cells (based on
counting of 50 cells per field in three randomly selected fields) are shown at the bottom of each panel in parenthesis. B. Ras-induced anchorage-
independent growth is reduced by knocking down IFN-b, IFNAR1 or ISG15. 10A/K-Ras cells were transiently transfected with different siRNAs. Three
days later, cells were used to perform soft agar colony formation assay as described in Materials and Methods. Results (number of colonies in soft
agar/well) were averages of triplicates. C. Ras-enhanced colony formation is reversed by knocking down IFN-b, IFNAR1, or ISG15. 10A/K-Ras cells were
transiently transfected with different siRNAs. Three days post-transfection, untreated and transfected cells were trypsinized, counted and seeded in
35 mm plates (500 cells/plate) in triplicates per treatment. After culturing for 10 days, colonies were stained with methylene blue and counted.
Results (number of colonies/plate) were averages of triplicates (* indicates p-value ,0.05). All experiments have been repeated once with similar
results.
doi:10.1371/journal.pone.0024291.g004
Interferon Signaling in Ras Transformation
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e24291could be dictated by the genetic makeup of the tumor cells. It is
well known that tumor cells can develop various immune escape
mechanisms through mutations, including MHC class I deficien-
cies, to escape from IFN-mediated immune suppression [33]. For
example, MHC class I deficiencies (e.g. mutations of the HLA
genes and defects in the components of the antigen processing
machinery) occur at near 100% frequency in some types of tumors
[33]. It seems possible that tumor cells may also adopt different
mechanisms to escape the growth inhibitory activities of type I
IFNs (e.g. BT474 cells, which do not express detectable ISG15,
could have inactivated the IFN signaling pathway through
mutations to escape either the immune suppressive or the
growth-inhibitory activities of IFNs). Consequently, many tumors
may have escaped the growth suppressive activities of type I IFNs,
but retain their dependence on type I IFNs for anchorage-
independent growth and metastasis. It is also important to point
out that the activities of type I IFN signaling may also involve
modulations by the complex cytokine network in the tumor
microenvironment. Clearly, further studies are necessary to clarify
the role of type I IFN signaling in tumorigenesis.
Materials and Methods
Cells and cell culture
ZR-75-1, BT474 and T47D cells [4,34] were cultured in RPMI
supplemented with 10% Fetalplex (Gemini Bio-Products, West
Sacramento, CA, USA), L-glutamine (2 mM), penicillin (100
units/ml) and streptomycin (100 mg/ml) in a 37uC incubator with
Figure 5. IFN-b autocrine signaling through ISG15 contributes to migratory properties of Ras-transformed MCF-10A cells. A.
Oncogenic Ras-elevated cell motility is reversed by knocking down IFN-b, IFNAR1, or ISG15. 10A/K-Ras cells were transiently transfected with different
siRNA. 24 hrs post-transfection, cells were trypsinized, seeded and cultured overnight to reach 100% confluence, followed by assaying wound healing
efficiency as described in Materials and Methods. The percentage of wound area in the viewing fields from 3 different images per treatment is
summarized. B. Cellular E-cadherin expression is restored by knocking down IFN-b, IFNAR1 or ISG15 in Ras-transformed cells. 10A/K-Ras cells were
transfected with various siRNAs. Two days post-transfection, cells were trypsinized and seeded onto cover slips pre-coated with poly-L-Lysine and
fibronectin. After culturing for one day, cells were processed for E-cadherin staining (in red) as described in Materials and Methods. C. IFN-b autocrine
signaling through ISG15 modulates E-cadherin in Ras-transformed cells. 10A/Ct and 10A/K-Ras cells were transfected with various siRNAs for 3 days.
Cell lysates were immunoblotted with various antibodies.
doi:10.1371/journal.pone.0024291.g005
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transformed NIH 3T3 cells were cultured similarly except using
DMEM instead of RPMI. MCF-10A and MCF-10AT cells were
cultured in Advanced DMEM/F12 (Invitrogen, Carlsbad, CA,
USA) supplemented with 5% equine serum (Invitrogen), 20 ng/ml
recombinant human EGF (Invitrogen), 10 mg/ml insulin (Sigma,
St. Louis, MO, USA), 0.5 mg/ml hydrocortisone (Sigma), 100 ng/
ml cholera toxin (Sigma), L-glutamine (2 mM), penicillin (100
units/ml) and streptomycin (100 mg/ml) in a 37uC incubator with
5% CO2.
Immunoblotting
Cells with various treatments were lysed with 6X sample buffer.
After boiling for 10 min, cell lysates were analyzed by SDS-PAGE
followed by immunoblotting with the appropriate antibody. The
following antibodies were used: IFNAR1 (ab45172; Abcam,
Cambridge, MA, USA), E-cadherin (#3195; Cell Signaling
Technology), IkBa (#4814; Cell Signaling Technology), phospho-
IkBa (#9246; Cell Signaling Technology) and b-actin (#4970; Cell
Signaling Technology). Visualization of bands was performed using
SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rock-
ford, IL, USA) and Kodak Image Station 2000R.
Interferon antiviral assay
Antiviral assays were performed as previously described [35]. In
brief, MDBK (for determining the concentration of IFN-a)o r
A549 cells (for determining the combined concentration of IFN-a
and IFN-b) were plated in 96-well plates containing 2-fold serial-
diluted laboratory standard IFN-a, or IFN-b, or conditioned
media from different cancer cells. VSV (vesicular stomatitis virus)
and EMCV (encephalomyocarditis virus) were later added into
MDBK and A549 cells, respectively. When cells in wells
containing no interferon were lysed by virus, plates were drained
and stained with crystal violet to visualize live cells. Interferon
concentrations were determined by comparing results to labora-
tory standard IFNs.
siRNA knockdown
siRNA against IFN-b (s7189, Ambion, Austin, TX, USA),
IFNAR1 (s783, Ambion), ISG15 (s228517, Ambion), and control
siRNA (SIC001, Sigma) were transfected into cells using
Oligofectamine transfection reagent (Invitrogen). The specific
conditions for each knockdown experiment are described in the
figure legends.
Construction of transformed MCF-10A cells
MCF-10A cells were transfected with control vector (pCEV29),
oncogenic H-Ras (pCEV29-H-RasR12) and oncogenic K-Ras
(pCEV29-K-RasV12) expressing vectors using FuGene transfec-
tion reagent (Roche) to create 10A/Ct, 10A/H-Ras and 10A/K-
Ras cells, respectively. Three days post transfection, cells were
replenished with 800 mg/ml G-418 (Invitrogen)-containing fresh
medium, and repeated passages were performed in the same
media until cells became resistant to G-418.
Soft agar colony formation assay
Cells (3610
3) were seeded in 2 ml of 0.35% agar (Sigma)
supplemented with complete MCF-10A medium. This suspension
was layered over 2 ml of 0.6% agar-medium base in each well of a
6-well plate. 2 ml of complete medium was added after the agar
was solidified. Cells were replenished with fresh media every week
for 3 weeks, followed by staining with 1 mg/ml p-Iodonitrote-
trazolium violet. Colonies larger than 0.2 mm in diameter were
counted using MiniCount (Imaging Products International).
Wound healing assay
10A/Ct and 10A/K-Ras cells were transfected with various
siRNAs. 24 hrs post-transfection, transfected cells were seeded at a
density of 1.3610
6 cells/35 mm plate. After another 24 hrs, cells
were replenished with 1 mg/ml mitomycin C (Sigma)-containing
fresh media. The wound was created by scratching cells with
pipette tips (200 ml tips). Images of wound areas were taken at 0
and 12 hr after scratching. Analysis of the wound area (expressed
in percentage of the total imaged area) was performed using the
ImageJ program.
Immunofluorescence and confocal microscopy
Various MCF-10A cells were transfected with and without
siRNAs (as indicated in the figures) for 48 hrs. Transfected cells
were then plated onto poly-L-Lysine- and fibronectin-coated
coverslips. 24 hrs after seeding, cells were fixed at room
temperature for 10 min in phosphate-buffered saline (pH 7.4)
with 4% paraformaldehyde (Electron Microscopy Sciences,
Hatfield, PA, USA) and permeabilized in phosphate-buffered
saline with 0.2% Triton X-100 (Fisher Scientific, Waltham, MA,
USA) followed by treatment with 10% BSA in phosphate-buffered
saline for 1 hr. Primary (rabbit) antibodies against E-cadherin
were incubated with samples for 8 hrs followed by incubation with
a secondary antibody (Cy3 goat antibody against rabbit IgG)
(Jackson ImmunoResearch Laboratories, West Grove, PA, USA).
The images were captured using a Zeiss LSM 410 confocal
microscope with a 568-nm excitation wavelength and a 610-nm
band pass emission filter. The pinhole size used was 30 Airy Units,
and the contrast/brightness settings were kept the same for all
images.
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